These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 27058353)

  • 1. Increasing HIV-1 pretreatment drug resistance among antiretroviral-naïve adults initiating treatment between 2006 and 2014 in Nairobi, Kenya.
    Chung MH; Silverman R; Beck IA; Yatich N; Dross S; McKernan-Mullin J; Bii S; Tapia K; Stern J; Chohan B; Sakr SR; Kiarie JN; Frenkel LM
    AIDS; 2016 Jun; 30(10):1680-2. PubMed ID: 27058353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya.
    Chung MH; Beck IA; Dross S; Tapia K; Kiarie JN; Richardson BA; Overbaugh J; Sakr SR; John-Stewart GC; Frenkel LM
    J Acquir Immune Defic Syndr; 2014 Nov; 67(3):246-53. PubMed ID: 25140907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru.
    Soria J; Mugruza R; Levine M; León SR; Arévalo J; Ticona E; Beck IA; Frenkel LM
    AIDS Res Hum Retroviruses; 2019 Feb; 35(2):150-154. PubMed ID: 30560685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of Pre-antiretroviral-Treatment Drug Resistance by Gender, Age, and Other Factors in HIV-Infected Individuals Initiating Therapy in Kenya, 2013-2014.
    Silverman RA; Beck IA; Kiptinness C; Levine M; Milne R; McGrath CJ; Bii S; Richardson BA; John-Stewart G; Chohan B; Sakr SR; Kiarie JN; Frenkel LM; Chung MH
    J Infect Dis; 2017 Dec; 216(12):1569-1578. PubMed ID: 29040633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of human immunodeficiency virus-1 drug-resistant mutations among adults on first- and second-line antiretroviral therapy in a resource-limited health facility in Busia County, Kenya.
    Makwaga O; Adhiambo M; Mulama DH; Muoma J; Adungo F; Wanjiku H; Ongaya A; Maitha GM; Mwau M
    Pan Afr Med J; 2020; 37():311. PubMed ID: 33654530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya.
    Onywera H; Maman D; Inzaule S; Auma E; Were K; Fredrick H; Owiti P; Opollo V; Etard JF; Mukui I; Kim AA; Zeh C
    PLoS One; 2017; 12(2):e0171124. PubMed ID: 28178281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV type 1 subtype diversity and drug resistance among HIV type 1-infected Kenyan patients initiating antiretroviral therapy.
    Lihana RW; Khamadi SA; Lubano K; Lwembe R; Kiptoo MK; Lagat N; Kinyua JG; Okoth FA; Songok EM; Makokha EP; Ichimura H
    AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1211-7. PubMed ID: 19954302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV type 1 drug resistance patterns among patients failing first and second line antiretroviral therapy in Nairobi, Kenya.
    Koigi P; Ngayo MO; Khamadi S; Ngugi C; Nyamache AK
    BMC Res Notes; 2014 Dec; 7():890. PubMed ID: 25487529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients.
    Metzner KJ; Rauch P; Braun P; Knechten H; Ehret R; Korn K; Kaiser R; Sichtig N; Ranneberg B; van Lunzen J; Walter H
    J Clin Virol; 2011 Feb; 50(2):156-61. PubMed ID: 21056001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
    Margot NA; Enejosa J; Cheng AK; Miller MD; McColl DJ;
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):209-21. PubMed ID: 19644384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.
    Guo W; Han J; Zhuang D; Liu S; Liu Y; Li L; Li H; Bao Z; Wang F; Li J
    Virol J; 2015 Nov; 12():187. PubMed ID: 26578099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
    Mulu A; Maier M; Liebert UG
    PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.
    Escoto-Delgadillo M; Vázquez-Valls E; Ramírez-Rodríguez M; Corona-Nakamura A; Amaya-Tapia G; Quintero-Pérez N; Panduro-Cerda A; Torres-Mendoza BM
    HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
    Lambert-Niclot S; Charpentier C; Storto A; Fofana DB; Soulié C; Fourati S; Visseaux B; Wirden M; Morand-Joubert L; Masquelier B; Flandre P; Calvez V; Descamps D; Marcelin AG
    J Antimicrob Chemother; 2013 Jun; 68(6):1237-42. PubMed ID: 23361642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.
    Geretti AM; Fox ZV; Booth CL; Smith CJ; Phillips AN; Johnson M; Li JF; Heneine W; Johnson JA
    J Acquir Immune Defic Syndr; 2009 Dec; 52(5):569-73. PubMed ID: 19779307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Diversity and Drug Resistance Among Antiretroviral Treatment-Failed Individuals from 2010 to 2012 in Honghe, China.
    Yang C; Yang S; Li J; Yang B; Liu J; Li H; Bian Z
    AIDS Res Hum Retroviruses; 2015 Aug; 31(8):822-9. PubMed ID: 25919896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.
    Miti S; Handema R; Mulenga L; Mwansa JK; Abrams E; Frimpong C; Burke VM; Zulu M; Siwingwa M; Mwakazanga D; Kalibala S; Denison JA
    PLoS One; 2020; 15(8):e0236156. PubMed ID: 32804970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.
    Metzner KJ; Scherrer AU; von Wyl V; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Hirsch HH; Vernazza PL; Cavassini M; Calmy A; Bernasconi E; Weber R; Günthard HF;
    AIDS; 2014 Sep; 28(15):2231-9. PubMed ID: 25036184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010.
    Charpentier C; Lambert-Niclot S; Visseaux B; Morand-Joubert L; Storto A; Larrouy L; Landman R; Calvez V; Marcelin AG; Descamps D
    J Antimicrob Chemother; 2013 Oct; 68(10):2197-8. PubMed ID: 23749952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Near point-of-care, point-mutation test to detect drug resistance in HIV-1: a validation study in a Mexican cohort.
    Panpradist N; Beck IA; Ruth PS; Ávila-Ríos S; García-Morales C; Soto-Nava M; Tapia-Trejo D; Matías-Florentino M; Paz-Juarez HE; Del Arenal-Sanchez S; Reyes-Terán G; Lutz BR; Frenkel LM
    AIDS; 2020 Jul; 34(9):1331-1338. PubMed ID: 32205723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.